| Budget Amount *help |
¥18,850,000 (Direct Cost: ¥14,500,000、Indirect Cost: ¥4,350,000)
Fiscal Year 2013: ¥5,590,000 (Direct Cost: ¥4,300,000、Indirect Cost: ¥1,290,000)
Fiscal Year 2012: ¥5,720,000 (Direct Cost: ¥4,400,000、Indirect Cost: ¥1,320,000)
Fiscal Year 2011: ¥7,540,000 (Direct Cost: ¥5,800,000、Indirect Cost: ¥1,740,000)
|
|---|
| Research Abstract |
In this study, we performed a comprehensive genetic analysis by using a newly developed system for fusion-gene detection and whole exome analysis, in order to identify novel genetic abnormalities responsible for myeloproliferative neoplasm (MPN) and to develop a new therapeutic option. We could detect several candidate regions with altered genomic structures which would contribute to produce novel fusion-genes. In addition, many novel missense mutations were found in MPN cases by whole exome analysis, however, they are not shared among cases. We are applying CRISPR method to patients' derived iPSs in order to clarify genetic functions of those mutations. Furthermore, we found out that peptides derived from those mutations could be presented to patients' HLA molecules and be recognized by T cells. We are preparing a protocol to provide patients a novel therapeutic option as genetic analysis-based personalized immunotherapy.
|
